Adverum Biotechnologies Inc ADVM-022 Update Call Transcript
Good afternoon, and welcome to the Adverum Biotechnologies Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to hand the call over to Amy Figueroa, Vice President of Investor Relations and Corporate Communications of Adverum. Please go ahead.
Thank you, Paul.
Good afternoon. Thank you for joining today's call to discuss an update on the ADVM-022 gene therapy program. A copy of the press release is available in the Investor Relations section of our corporate website at www.adverum.com. Please note that a replay of today's call will be available on the Events and Presentations section of our website.
Joining me today is Dr. Laurent Fischer, President and Chief Executive Officer; and Dr. Julie Clark, Chief Medical Officer. In addition, we are joined by Dr. Szilárd Kiss, Associate Professor in Ophthalmology and Member of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |